Nihon TRIM Co. develops umbilical cord-derived mesenchymal stem cells for treatment of severe acute graft-versus-host disease

Main product of the company is electrolyzed reduced water (ERW) which is claimed to have antioxidant properties. Its newly founded subsidiary, Human Life Cord Japan, will develop regenerative medicine products. The first project is with the University of Tokyo Institute of Medical Science on MSC derived from umbilical cord, and further projects concern rare diseases such as the treatment of blood cell phagocytosis syndrome

Source: Human Life Cord news release, September 5, 2017

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint